Demyelinating neuropathy with anti-crmp5 antibodies predating diagnosis of breast carcinoma: Favorable outcome after cancer therapy

Muscle and Nerve

Volumn 43, Issue 5, 2011, Pages 764-766

  Samarasekera, Shanika ^a   Rajabally, Yusuf A ^a  

^a UNIVERSITY HOSPITALS OF LEICESTER NHS TRUST   (United Kingdom)

Author keywords

Breast; Carcinoma; Crmp5; Demyelinating; Inflammatory; Neuropathy; Paraneoplastic

Indexed keywords

ANTIBODY; COLLAPSIN RESPONSE MEDIATOR PROTEIN 5 ANTIBODY; CYCLOPHOSPHAMIDE; EPIRUBICIN; FLUOROURACIL; LETROZOLE; PREGABALIN; UNCLASSIFIED DRUG;

AGED; ARTICLE; BREAST CARCINOMA; CANCER COMBINATION CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER HORMONE THERAPY; CANCER RADIOTHERAPY; CANCER REGRESSION; CANCER THERAPY; CASE REPORT; DEMYELINATING NEUROPATHY; DISEASE ASSOCIATION; FEMALE; FOLLOW UP; HUMAN; IGG KAPPA MONOCLONAL GAMMOPATHY OF UNCERTAIN SIGNIFICANCE; MONOCLONAL IMMUNOGLOBULINEMIA; NEUROLOGIC EXAMINATION; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROGNOSIS; SENSORY ATAXIC DEMYELINATING NEUROPATHY; SENSORY SYSTEM ELECTROPHYSIOLOGY; WESTERN BLOTTING;

AGED; AUTOANTIBODIES; BREAST NEOPLASMS; CARCINOMA; DEMYELINATING DISEASES; FEMALE; HUMANS; NERVE TISSUE PROTEINS; POLYNEUROPATHIES; TREATMENT OUTCOME;

EID: 79955556030     PISSN: 0148639X     EISSN: 10974598     Source Type: Journal    
DOI: 10.1002/mus.22036     Document Type: Article

References (12)

1. Gatti G, Simsek S, Kurne A, Zurrida S, Naninato P, Veronesi P, et al. Paraneoplastic neurological disorders in breast cancer. Breast 2003; 12:203-207.
2. Altaha R, Abraham J. Paraneoplastic neurologic syndrome associated with occult breast cancer: a case report and review of the literature. Breast J 2003;9:417-419.
3. Rojas-Marcos I, Rousseau A, Keime-Guibert F, Reñé R, Cartalat-Carel S, Delattre RL, et al. Spectrum of paraneoplastic neurologic disorders in women with breast and gynecologic cancer. Medicine (Baltimore) 2003;82:216-223.
4. Rajabally YA, Qaddoura B, Abbott RJ. Steroid-responsive paraneoplastic demyelinating neuropathy and myelopathy associated with breast carcinoma. J Clin Neuromuscul Dis 2008;10:65-69.
5. Honnorat J, Cartalat-Carel S, Ricard D, Camdessanche JP, Carpentier AF, Rogemond V, et al. Onco-neural antibodies and tumour type determine survival and neurological symptoms in paraneoplastic neurological syndromes with Hu or CV2/CRMP5 antibodies. J Neurol Neurosurg Psychiatry 2009;80:412-416.
6. Smitt PA, Polman SK, de Beukelaar JW, Enting RH, van den Bent MA, Bromberg JE, et al. Three patients with a paraneoplastic neurological syndrome: the significance of paraneoplastic antibodies. Ned Tijdschr Geneeskd 2007;151:874-880.
7. Yu Z, Kryzer TJ, Griesmann GE, Kim K, Bennaroch EE, Lennon VA. CRMP5 neuronal antibody: marker of lung cancer and thymomarelated autoimmunity. Ann Neurol 2001;49:146-154.
8. Hadden RD, Nobile-Orazio E, Sommer C, Hahn A, Illa I, Morra E, et al. European Federation of Neurological Societies/Peripheral Nerve Society guideline on management of paraproteinaemic demyelinating neuropathies: report of a joint task force of the European Federation of Neurological Societies and the Peripheral Nerve Society. Eur J Neurol 2006;13:809-818.
9. van den Bergh PY, Hadden RD, Bouche P, Cornblath DR, Hahn A, Illa I, et al. European Federation of Neurological Societies/Peripheral Nerve Society guideline on management of chronic inflammatory demyelinating polyneuropathy: report of a joint task force of the European Federation of Neurological Societies and the Peripheral Nerve Society-first revision. Eur J Neurol 2010;17: 356-363.
10. Yagi Y, Inuzka T, Takada K, Nakano R, Hozumi I, Yoshimoto H, et al. Changes in anti-HuD antibody titers in the long-term course in paraneoplastic sensory neuropathy. Eur Neurol 1997;37:122-123.
11. Tanaka K, Tanaka M, Igarashi S, Onodera O, Nakajima T, Yamazaki M, et al. Long-term course of change in anti-Yo antibody content in paraneoplastic cerebellar degeneration. J Neurol Neurosurg Psychiatry 1995:58:256-257.
12. Lladó A, Mannucci P, Carpentier AF, Paris S, Blanco Y, Saiz A, et al. Value of Hu antibody determinations in the follow-up of paraneoplastic neurologic syndromes. Neurology 2004;63: 1947-1949.